SPOTLIGHT -
Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients
This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.
